Certara (NASDAQ:CERT) Trading Up 5%

Certara, Inc. (NASDAQ:CERT)’s stock price shot up 5% during trading on Tuesday . The stock traded as high as $11.25 and last traded at $11.23. 195,202 shares traded hands during trading, a decline of 72% from the average session volume of 701,611 shares. The stock had previously closed at $10.70.

Analyst Upgrades and Downgrades

CERT has been the topic of several recent research reports. KeyCorp reduced their price target on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. JMP Securities restated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Barclays dropped their target price on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. UBS Group reduced their price target on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, Robert W. Baird lowered their price objective on Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Certara currently has an average rating of “Hold” and a consensus target price of $17.79.

Certara Trading Up 1.8 %

The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. The company has a market cap of $1.75 billion, a P/E ratio of -27.44, a P/E/G ratio of 5.23 and a beta of 1.49. The business has a fifty day simple moving average of $13.54 and a 200 day simple moving average of $15.56.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS. Analysts anticipate that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.39% of the stock is owned by company insiders.

Institutional Trading of Certara

Several hedge funds have recently bought and sold shares of the company. Mubadala Investment Co PJSC acquired a new stake in shares of Certara in the fourth quarter valued at approximately $169,135,000. Wasatch Advisors LP increased its position in Certara by 23.4% in the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after acquiring an additional 932,598 shares during the period. Geneva Capital Management LLC increased its position in Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after acquiring an additional 579,349 shares during the period. Clearbridge Investments LLC raised its stake in Certara by 0.8% during the 1st quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after acquiring an additional 32,846 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after purchasing an additional 273,095 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.